

Product datasheet for **TL314124V**

CCR7 Human shRNA Lentiviral Particle (Locus ID 1236)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CCR7 Human shRNA Lentiviral Particle (Locus ID 1236)
Locus ID:	1236
Synonyms:	BLR2; CC-CKR-7; CCR-7; CD197; CDw197; CMKBR7; EBI1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CCR7 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001301714 , NM_001301716 , NM_001301717 , NM_001301718 , NM_001838 , NM_001838.1 , NM_001838.2 , NM_001838.3 , NM_001301714.1 , NM_001301716.1 , NM_001301717.1 , NM_001301718.1 , BC035343 , BC035343.1 , NM_001301714.2 , NM_001838.4
UniProt ID:	P32248
Summary:	The protein encoded by this gene is a member of the G protein-coupled receptor family. This receptor was identified as a gene induced by the Epstein-Barr virus (EBV), and is thought to be a mediator of EBV effects on B lymphocytes. This receptor is expressed in various lymphoid tissues and activates B and T lymphocytes. It has been shown to control the migration of memory T cells to inflamed tissues, as well as stimulate dendritic cell maturation. The chemokine (C-C motif) ligand 19 (CCL19/ECL) has been reported to be a specific ligand of this receptor. Signals mediated by this receptor regulate T cell homeostasis in lymph nodes, and may also function in the activation and polarization of T cells, and in chronic inflammation pathogenesis. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Sep 2014]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).